Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Plant protein drink may shield aging Hearts—A trial puts it to the test

NCT ID NCT04923555

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time

Summary

This trial tests whether a single yogurt drink made from vegetable proteins rich in leucine, cysteine, and arginine can improve blood vessel function and reduce inflammation in older adults with cardiometabolic risk. Participants, aged 65 and older, will consume either the vegetable protein drink or an animal protein version, and researchers will measure how well their blood vessels dilate before and after. The goal is to see if plant-based proteins can be a heart-healthy alternative to animal proteins for aging populations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A yogurt drink made with vegetable proteins rich in leucine, cysteine, and arginine
What this could lead to
If effective, this could support recommendations to replace animal proteins with plant-based options in older adults without harming heart health, and possibly improve vascular function.
What could go wrong
This is a small, early-stage trial with only 33 participants, so results may not apply broadly. The drink is tested only once, so any effects might be short-lived and not reflect long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

33 people

The number who actually took part.

Started

Nov 2021

Finished

Jun 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Man or woman * 65 years old and older (inclusive) * At least 2 of the following 4 cardiometabolic factors: * Waist circumference ≥88 cm for women, and ≥94 cm for men * Fasting triglyceridemia \>1,5 g/L OR HDL level \< 40 mg/dl for men, and \< 50 mg/dl for women * Fasting blood glucose ≥ 100 mg/dl * Systolic blood pressure \>130mmHg ou diastolic \> 85 mm Hg * Accept not to change his lifestyle throughout the study * Accept to consume the same meal the day before exploration days, making sure to exclude non-recommended foods and agreeing to detail its content in a food diary * Ability to give informed consent to participate in research * Affiliation to Social Security Exclusion Criteria: * Acute pathology (unstable or terminal pathology) * Renal failure (clearance \<40 mL / min) * Asthma or chronic respiratory disease * Systolic or diastolic blood pressure in the judgement of the investigator * Diabetic (treated or not) * Treated with chemotherapy * Gastrointestinal, thyroid, cardiac or vascular illness in the judgement of the investigator * Biological examination no compatible with the study in the judgement of the investigator * Medical and/or surgical history no compatible with the study in the judgement of the investigator (previous cardiovascular events) * AgHbS, AcHbc, HCV and HIV positive serology * Concomitant treatment no compatible with the study in the judgement of the investigator * Diet or change in body mass \> 2 kg in the 30 days before the study * Following a diet incompatible with the nutritional protocol (food intolerances, vegans, exclusion of certain food ingredients) * Allergies to any of the components of the test meals * Alcohol consumption\> 2 glasses / day * Current smokers (\> 6 cigarettes per week) * Subjects involved in another clinical trial or being in the exclusion period of another study or having received a total compensation greater than 4,500 euros over the 12 months preceding the start of the trial * Subject benefiting from a legal protection measure (curatorship, guardianship, safeguard of justice) * Refusal to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CHU clermont-ferrand

    Clermont-Ferrand, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.